Patient and physician delay in the diagnosis and treatment of non-small cell lung cancer in Turkey

Yurdakul, Ahmet Selim; Kocatürk, Celalettin; Bayız, Hülya; Gürsoy, Soner; Bircan, Ahmet; Özcan, Ayşenaz; Akkoçlu, Atilla; Uluorman, Funda; Çeli̇k, Pınar; Köksal, Deniz; Ulubaş, Bahar; Sercan, Eylem; Özbudak, Ömer; Göksel, Tuncay; Önalan, Tuğba; Yamansavci, Esra; Türk, Figen; Yuncu, Gökhan; Çopuraslan, Çiğdem; Mardal, Tuğba; Tuncay, Esin; Karamustafaoğlu, Yekta Altemur; Yıldız, Pınar; Seçik, Funda; Kaplan, Muhammet Ali; Caglar, Emel; Ortaköylü, Mediha Gönenç; Önal, Mine; Turna, Akif; Hekimoglu, E.; Dalar, Levent; Altın, Sedat; Gülhan, Meral; Akpınar, Evrim Eylem; Savaş, İsmail; Firat, Nalan; Çamsari, Güngör; Özkan, Gülçihan; Çetınkaya, Erdoğan; Kamiloglu, Emine; Çelik, Bülent; Havlucu, Yavuz

doi:10.1016/j.canep.2014.12.015

Cited by 20 publications

(31 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total sample size from primary studies was 3133 participants. An average of 2233 were predominately male from nine studies and 803 females [33][34][35][36][37][38][39][40][41], one study [42] did not specify on the sex of the participants. About smoking status, six studies showed significant male predominance [33-35, 38, 40, 41].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…About smoking status, six studies showed significant male predominance [33-35, 38, 40, 41]. Of the ten included studies, 4 were retrospective studies [33,34,36,41]; 3 were prospective studies [38,40,42]; 2 were descriptive studies [37,39] and 1 was cross-sectional study [35]. All the ten studies described at least one interval in lung cancer care.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…All the ten studies described at least one interval in lung cancer care. Three studies reported that most patients visited two or more GPs before a confirmation of their diagnosis [37,40,42]. Eight studies showed median time from symptom onset to diagnosis [33-35, 37-40, 42].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Eight studies showed median time from symptom onset to diagnosis [33-35, 37-40, 42]. Seven studies showed reasons for misdiagnosis and misinterpretations of findings among the GPs [34,35,[37][38][39][40]42]. Characteristics of the included studies are presented in Table 1.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…The studies were assessed based on all the categorized domains. All the ten included studies had high quality percentage of 76-100% ( [33][34][35][36][37][38][39][40][41][42]. None of the ten included studies for quality assessment scored low quality (<50%) percentage.…”

Section: Quality Of Evidence From Included Primary Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Health systems influence on the pathways of care for lung cancer in low- and middle-income countries: a scoping review

2020

View full text Add to dashboard Cite

Background: Globally, lung cancer is the most common cancer and cause of cancer-related deaths, responsible for nearly one in five deaths. Many health systems in low-and middle-income countries, including sub-Saharan Africa have weak organizational structure, which results in delayed lead time for lung cancer patient care continuum from diagnosis to palliative care. Aim: To map evidence on the health systems issues impacting on the delays in timely lung cancer care continuum from diagnosis to palliative care in LMICs, including sub-Saharan Africa. Methods: A scoping review was performed following the method of Arksey and O'Malley. Systematic searches were performed using EBSCOhost platform, a keyword search from the following electronic databases were conducted: PubMed/MEDLINE, Google Scholar, Science Direct, World Health Organization (WHO) library, and grey literature. The screening was guided by the inclusion and exclusion criteria. The quality of the included studies was determined by Mixed Method Appraisal Tool (MMAT). Results: A total of 2886 articles were screened, and 236 met the eligibility criteria for this scoping review study. Furthermore, 155 articles were also excluded following abstract screening. Eighty-one articles were selected for fullarticle screening by two researchers with 10 being selected for independent detailed data extraction for synthesis. These studies were also subjected to methodological quality assessment. All included studies were conducted in LMICs mostly Asia, the Middle East, and Latin America and published between January 2008 and June 2018. The ten included studies described at least one interval in lung cancer care. Conclusions: Reducing wait time across this care continuum is needed to improve easy access to healthcare, quality care, survival and patient outcomes, as many patients still face longer wait times for diagnosis and treatment of lung cancer than recommended in several healthcare settings. A multidisciplinary team approach will help to reduce wait time and ensure that all patients receive appropriate care. Interventions are needed to address delays in lung cancer care in LMICs. Health-care providers at all levels of care should be educated and equipped with skills to identify lung cancer symptoms and perform or refer for appropriate diagnostic tests.

show abstract

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Quality Of Evidence From Included Primary Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Health systems influence on the pathways of care for lung cancer in low- and middle-income countries: a scoping review

2020

View full text Add to dashboard Cite

show abstract

Evaluating the Time Interval Between Symptoms Onset, Diagnosis, and Therapeutic Intervention in Lung Cancer: A Cross‐Sectional Study in Southern Iran

Salehi,

Rezvani,

Fallahi

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

Background and AimDelay in diagnosis and treatment of lung cancer is thought to be a major cause of its poor outcomes. We evaluated the delays within the presentation to the initiation of diagnostic and therapeutic interventions amongst lung cancer patients in Southern Iran.MethodsThis cross‐sectional study was conducted from March 2019 to March 2021. The data collected through interview included socio‐demographic, medical and clinical findings, and the time intervals needed to visit physician, refer to specialist, request diagnostic procedures, reach diagnosis of lung cancer, and hospitalization.ResultsEighty‐nine patients (58 males and 31 females) with a mean age of 61.01 ± 12.25 years were included. The median time of symptom presentation and first physician visit interval was 25 days. Sixty‐five days were spent for requesting, performing, and evaluating the diagnostic procedures. The median interval between diagnosis and initiation of treatment was 16 days. Totally, it took an average of 122 days from the presentation to the definite diagnosis of lung cancer. Patient‐, diagnosis‐, and treatment‐related delays were not significantly correlated with any of the demographic, socioeconomic, and clinical (disease stage, symptom) variables, as well as the diagnosis tool and the first physician who visited the patient (p > 0.05).ConclusionsThere was a significant delay but relatively similar to other countries in the diagnosis and treatment of lung cancer patients in Southern Iran. The largest portion of delay could be attributed to the raising clinical suspicion in the physicians, referral for diagnostic assessments, and the diagnosis process.

show abstract

Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients

Salim

Telli

Tatlı

et al. 2019

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Patient and physician delay in the diagnosis and treatment of non-small cell lung cancer in Turkey

Cited by 20 publications

References 30 publications

Health systems influence on the pathways of care for lung cancer in low- and middle-income countries: a scoping review

Health systems influence on the pathways of care for lung cancer in low- and middle-income countries: a scoping review

Evaluating the Time Interval Between Symptoms Onset, Diagnosis, and Therapeutic Intervention in Lung Cancer: A Cross‐Sectional Study in Southern Iran

Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients

Contact Info

Product

Resources

About